There is nothing positive about losing an experien

There is nothing positive about losing an experienced executive but I personally wish Dr. Bertolino well. I think Dr. B was instrumental in the decisions to pursue both the OM and IBD markets with Brilacidin. I believe that both of these initiatives will pay huge benefits to IPIX shareholders over the Long Term. I have zero insight into his departure but it could be for a variety of reasons including pursuing an opportunity too good to pass up or possibly it could be a difference of opinion on choosing between strategic options or directions for IPIX. I believe Locust Walk is pursuing various options that IPIX will entertain and they COULD include strategic license agreements, sale of specific assets or an outright purchase of IPIX. My personal belief is that Leo is playing Long-ball and is looking to maximize LONG TERM value of IPIX’s science and in turn shareholder value. I am hopeful that Dr. B’s replacement has a strong background in Cancer and will be able to help advance Kevetrin towards market approval. I believe that Brilacidin is positioned well for both OM and IBD where partnerships could take control of them and get them to market.